{
}
Editas Medicine will lay off 180 employees, about two-thirds of its workforce, as it shifts focus to “in vivo” gene editing after failing to find a partner for its sickle cell therapy. The company is ending development of its lead CRISPR medicine and will share more preclinical data in early 2025.
Baisong Mei
People
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
editas medicine lays off staff and shifts focus to in vivo gene editing
United States Dollar
bluebird bio, Inc.
CRISPR Therapeutics AG
Editas Medicine, Inc.
Baisong Mei
Gilmore O’Neill
Show more
01:00 12.12.2024
Trending
Subcategory
Industry Trends
Corporate News
Startups & Entrepreneurship
Retail and Consumer Goods
Supply Chain Management
Global Trade Developments
Government Economic Policies
Workplace Trends
Stock Market Updates
Industry Mergers & Acquisitions
Fintech Startups
Venture Capital Investments
Finance Mergers & Acquisitions
CEO Changes
Financial Scams and Security
Emerging Startups
Cryptocurrency Trends
Cryptocurrency & Blockchain Regulations
Funding Rounds & Investments
Energy Sector Developments
Countries:
Companies:
Apple Inc.
Google Inc.
Alphabet Inc.
NVIDIA Corporation
Tesla, Inc.
Microsoft Corporation
Amazon.com, Inc.
Delhivery Limited
Ecom Express Ltd.
Foxconn Technology Co., Ltd.
Samsung SDI Co., Ltd.
SWIGGY LIMITED
UWS JP Morgan EM A OSB
Netflix, Inc.
Airbnb, Inc.
Adobe Inc.
GEELY AUTO
TENCENT
CarTrade Tech Limited
Concrete Credit Limited
Currencies:
United States Dollar
Indian Rupee
Chinese Yuan
Euro
Japanese Yen
South Korean Won
Algerian Dinar
Vietnamese Đồng
Indonesian Rupiah
Australian Dollar
Egyptian Pound
Saudi Riyal
Swiss Franc
British Pound Sterling
Russian Ruble
Pakistani Rupee
People: